文献速递心境障碍

艾司氯胺酮抗抑郁作用的分子机制:超越NMDA受体

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
PubMed 文献 · Mol Psychiatry · 2021-05-07

本文综述了氯胺酮对映体艾司氯胺酮(arketamine)抗抑郁作用的分子机制。临床前研究显示艾司氯胺酮在啮齿类动物中比艾司氯胺酮(esketamine)具有更强、更持久的抗抑郁样效应,尽管其对NMDA受体亲和力较低;非氯胺酮NMDA受体相关化合物在抑郁症患者中未显示类似强效抗抑郁作用。文章还讨论了脑-肠-微生物轴和脑-脾轴在应激相关精神障碍及艾司氯胺酮抗抑郁样作用中的可能角色,并探讨艾司氯胺酮治疗认知损害、帕金森病、骨质疏松、炎症性肠病和卒中的潜力。

要点

  • 艾司氯胺酮在啮齿类动物中抗抑郁样效应比艾司氯胺酮更强更持久,尽管NMDA受体亲和力更低。
  • 非氯胺酮NMDA受体相关化合物在抑郁症患者中未显示氯胺酮样强效抗抑郁作用。
  • NMDA受体可能在氯胺酮及其对映体抗抑郁作用中不发挥主要作用。

核心结论

  • 现有研究表明NMDA受体不太可能在氯胺酮及其对映体抗抑郁作用中发挥主要作用,但精确分子机制仍不清楚。

研究设计与样本

  • 本文为综述,回顾近期关于氯胺酮及其对映体艾司氯胺酮抗抑郁作用分子机制的研究。

主要发现

  • 临床前研究显示艾司氯胺酮在啮齿类动物中比艾司氯胺酮具有更强、更持久的抗抑郁样效应,尽管其对NMDA受体亲和力较低。
  • 临床试验中非氯胺酮NMDA受体相关化合物在抑郁症患者中未显示氯胺酮样强效抗抑郁作用,尽管在啮齿类动物中显示抗抑郁样效应。
  • 啮齿类动物数据不一定能转化到人类,因人类精神障碍的复杂性。

临床怎么用

  • 综述提示艾司氯胺酮可能成为治疗精神障碍认知损害、帕金森病、骨质疏松、炎症性肠病和卒中的潜在选择。

局限性

  • 氯胺酮及其对映体抗抑郁作用的精确分子机制仍不清楚。
  • 啮齿类动物数据不一定能转化到人类,因人类精神障碍的复杂性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has been a crucial breakthrough in mood disorder research. (R,S)-ketamine is a racemic mixture of equal amounts of (R)-ketamine (arketamine) and (S)-ketamine (esketamine). In 2019, an esketamine nasal spray from Johnson & Johnson was approved in the United States of America and Europe for treatment-resistant depression. However, an increasing number of preclinical studies show that arketamine has greater potency and longer-lasting antidepressant-like effects than esketamine in rodents, despite the lower binding affinity of arketamine for the NMDAR. In clinical trials, non-ketamine NMDAR-related compounds did not exhibit ketamine-like robust antidepressant actions in patients with depression, despite these compounds showing antidepressant-like effects in rodents. Thus, the rodent data do not necessarily translate to humans due to the complexity of human psychiatric disorders. Collectively, the available studies indicate that it is unlikely that NMDAR plays a major role in the antidepressant action of (R,S)-ketamine and its enantiomers, although the precise molecular mechanisms underlying antidepressant actions of (R,S)-ketamine and its enantiomers remain unclear. In this paper, we review recent findings on the molecular mechanisms underlying the antidepressant actions of (R,S)-ketamine and its potent enantiomer arketamine. Furthermore, we discuss the possible role of the brain-gut-microbiota axis and brain-spleen axis in stress-related psychiatric disorders and in the antidepressant-like action of arketamine. Finally, we discuss the potential of arketamine as a treatment for cognitive impairment in psychiatric disorders, Parkinson's disease, osteoporosis, inflammatory bowel diseases, and stroke.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wei Y, Chang L, Hashimoto K, et al. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. 2021. PMID: 33963284. doi:10.1038/s41380-021-01121-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。